These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 10928059)

  • 41. Focus on acetylation: the role of histone deacetylase inhibitors in cancer therapy and beyond.
    Konstantinopoulos PA; Karamouzis MV; Papavassiliou AG
    Expert Opin Investig Drugs; 2007 May; 16(5):569-71. PubMed ID: 17461732
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mass spectrometry in epigenetic research.
    Beck HC
    Methods Mol Biol; 2010; 593():263-82. PubMed ID: 19957154
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Romidepsin reduces histone deacetylase activity, induces acetylation of histones, inhibits proliferation, and activates apoptosis in immortalized epithelial endometriotic cells.
    Imesch P; Fink D; Fedier A
    Fertil Steril; 2010 Dec; 94(7):2838-42. PubMed ID: 20605144
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Histone deacetylases: a new class of efficient anti-tumor drugs].
    Mottet D; Castronovo V
    Med Sci (Paris); 2008; 24(8-9):742-6. PubMed ID: 18789222
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Understanding histone deacetylases in the cancer development and treatment: an epigenetic perspective of cancer chemotherapy.
    Ahmad M; Hamid A; Hussain A; Majeed R; Qurishi Y; Bhat JA; Najar RA; Qazi AK; Zargar MA; Singh SK; Saxena AK
    DNA Cell Biol; 2012 Oct; 31 Suppl 1():S62-71. PubMed ID: 22462686
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The potential of histone deacetylase inhibitors in lung cancer.
    Aparicio A
    Clin Lung Cancer; 2006 Mar; 7(5):309-12. PubMed ID: 16640801
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Molecular pathways: old drugs define new pathways: non-histone acetylation at the crossroads of the DNA damage response and autophagy.
    Botrugno OA; Robert T; Vanoli F; Foiani M; Minucci S
    Clin Cancer Res; 2012 May; 18(9):2436-42. PubMed ID: 22512979
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Histone deacetylase inhibitors: mechanisms and clinical significance in cancer: HDAC inhibitor-induced apoptosis.
    Shankar S; Srivastava RK
    Adv Exp Med Biol; 2008; 615():261-98. PubMed ID: 18437899
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Inhibitors of histone deacetylase as new anticancer agents.
    Jung M
    Curr Med Chem; 2001 Oct; 8(12):1505-11. PubMed ID: 11562279
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The role of histone deacetylases (HDACs) in human cancer.
    Ropero S; Esteller M
    Mol Oncol; 2007 Jun; 1(1):19-25. PubMed ID: 19383284
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Targeting Histone Deacetylases with Natural and Synthetic Agents: An Emerging Anticancer Strategy.
    Singh AK; Bishayee A; Pandey AK
    Nutrients; 2018 Jun; 10(6):. PubMed ID: 29882797
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Histone deacetylase inhibitors in cancer therapy: latest developments, trends and medicinal chemistry perspective.
    Balakin KV; Ivanenkov YA; Kiselyov AS; Tkachenko SE
    Anticancer Agents Med Chem; 2007 Sep; 7(5):576-92. PubMed ID: 17896917
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Histone deacetylase inhibitors: a new wave of molecular targeted anticancer agents.
    Budillon A; Di Gennaro E; Bruzzese F; Rocco M; Manzo G; Caraglia M
    Recent Pat Anticancer Drug Discov; 2007 Jun; 2(2):119-34. PubMed ID: 18221057
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Short-chain fatty acid inhibitors of histone deacetylases: promising anticancer therapeutics?
    Chen JS; Faller DV; Spanjaard RA
    Curr Cancer Drug Targets; 2003 Jun; 3(3):219-36. PubMed ID: 12769690
    [TBL] [Abstract][Full Text] [Related]  

  • 55. CpG island methylation and histone modifications: biology and clinical significance.
    Esteller M
    Ernst Schering Res Found Workshop; 2006; (57):115-26. PubMed ID: 16568952
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Histone tail modifications and noncanonical functions of histones: perspectives in cancer epigenetics.
    Hadnagy A; Beaulieu R; Balicki D
    Mol Cancer Ther; 2008 Apr; 7(4):740-8. PubMed ID: 18413789
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Histone deacetylase inhibitors: from target to clinical trials.
    Kelly WK; O'Connor OA; Marks PA
    Expert Opin Investig Drugs; 2002 Dec; 11(12):1695-713. PubMed ID: 12457432
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Therapeutic potential for HDAC inhibitors in the heart.
    McKinsey TA
    Annu Rev Pharmacol Toxicol; 2012; 52():303-19. PubMed ID: 21942627
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Selective inhibitors of zinc-dependent histone deacetylases. Therapeutic targets relevant to cancer.
    Kollar J; Frecer V
    Curr Pharm Des; 2015; 21(11):1472-502. PubMed ID: 25382430
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Histone deacetylase inhibitors: design, structure-activity relationships and therapeutic implications for cancer.
    Marson CM
    Anticancer Agents Med Chem; 2009 Jul; 9(6):661-92. PubMed ID: 19601748
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.